Importantly, the identification of cells that show overexpression of PSCA in bone marrow and peripheral blood of patients with prostate cancer may be a much better indicator for detecting and predicting metastatic progression than tests that examine only PSA-positive or PSMA-positive [6]. This evidence concerns the gene FOLH1 and prostate carcinoma.